Thanks I never saw any follow ups on the news or even on this thread. It just was strange as quickly as it manifested itself it just as rapidly became a no story. So I guess the initial panic was unwarranted.
I wouldn't say that. Without treatment many of those kids could have died, and even with it, some of the kids have diabities, or other conidtions that they previously didn't have. In terms of fataltiies though much better.
Bob - not quite sure what your question is. I posted links to two studies on MIS-C (multisymptom inflammatory syndrome in children) at the end of June (linked below) and there have been a host of publications on MIS-C since then.
https://rutgers.forums.rivals.com/t...entions-and-more.191275/page-219#post-4621806
Just a couple of weeks ago an excellent editorial was published in the New England Journal of Medicine on MIS-C. As noted, it's pretty rare, but serious with hospitalization usually required and a small % of deaths observed. There are some who have said it's simply the childhood version of the inflammatory cytokine storm seen in older patients and responsible for a large % of deaths in older patients.
My guess is some of what's gone on is that early in the pandemic, it looked like children weren't having serious illnesses or dying and then data came in showing that at least a very small % were becoming quite ill and that possibly some of these cases had been thought to be non-COVID related (Kawasaki's Syndrome), plus, right or wrong, when children become very ill or die, it seems to be a bigger story than when this happens to the elderly.
https://www.nejm.org/doi/full/10.1056/NEJMe2023158?query=recirc_curatedRelated_article
Greg - not sure what "treatment" you're referring to. Anything more you can share? The articles I've seen and the editorial above make it sound like children with MIS-C are treated fairly similarly to adults with cytokine storm over-inflammation. I'm not sure we have had enough MIS-C patients to have done any controlled trials to know what might be effective, as per the commentary in the editorial, below.
The challenges of this new condition will now be to understand its pathophysiological mechanisms, to develop diagnostics, and to define the best treatment. Most patients to date have been treated with agents that have shown benefit in Kawasaki’s disease or other inflammatory disorders; thus, trials are needed to establish the appropriate therapy.